Search
Paclitaxel Treatment Options in United Kingdom
A collection of 293 research studies where Paclitaxel is the interventional treatment. These studies are located in the United Kingdom . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
49 - 60 of 293
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Active Not Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Duarte, California +226 locations
Research Site, Duarte, California
Research Site, Los Angeles, California
Research Site, San Francisco, California
Research Site, Grand Junction, Colorado
Research Site, Longmont, Colorado
Research Site, New Haven, Connecticut
Research Site, Washington, District of Columbia
Research Site, Miami, Florida
Research Site, Miami, Florida
Research Site, Atlanta, Georgia
Research Site, Louisville, Kentucky
Research Site, Detroit, Michigan
Research Site, Albuquerque, New Mexico
Research Site, New York, New York
Research Site, Charlotte, North Carolina
Research Site, Winston-Salem, North Carolina
Research Site, Providence, Rhode Island
Research Site, Sioux Falls, South Dakota
Research Site, Memphis, Tennessee
Research Site, Nashville, Tennessee
Research Site, Fort Worth, Texas
Research Site, Houston, Texas
Research Site, Kingwood, Texas
Research Site, San Antonio, Texas
Research Site, Charlottesville, Virginia
Research Site, Spokane Valley, Washington
Research Site, Madison, Wisconsin
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Caba, Not set
Research Site, Ciudad Autónoma Buenos Aires, Not set
Research Site, Mar del Plata, Not set
Research Site, Rosario, Not set
Research Site, Anderlecht, Not set
Research Site, Gent, Not set
Research Site, Namur, Not set
Research Site, Sint-Niklaas, Not set
Research Site, Wilrijk, Not set
Research Site, Brasilia, Not set
Research Site, Curitiba, Not set
Research Site, Goiânia, Not set
Research Site, Jaú, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Rio de Janeiro, Not set
Research Site, São Paulo, Not set
Research Site, São Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Calgary, Alberta
Research Site, Barrie, Ontario
Research Site, Hamilton, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Greenfield Park, Quebec
Research Site, Montreal, Quebec
Research Site, Quebec, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Bengbu, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hefei, Not set
Research Site, Hefei, Not set
Research Site, Ji Nan, Not set
Research Site, Jinan, Not set
Research Site, Nanchang, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Tianjin, Not set
Research Site, Xi'an, Not set
Research Site, Xian, Not set
Research Site, Zhengzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Bordeaux, Not set
Research Site, Dijon, Not set
Research Site, Limoges Cedex, Not set
Research Site, Lyon, Not set
Research Site, Marseille, Not set
Research Site, Montpellier, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint Herblain Cedex, Not set
Research Site, Tours, Not set
Research Site, Aschaffenburg, Not set
Research Site, Bonn, Not set
Research Site, Frankfurt am Main, Not set
Research Site, Georgsmarienhuette, Not set
Research Site, Hannover, Not set
Research Site, Heilbronn, Not set
Research Site, Koblenz Am Rhein, Not set
Research Site, Langen, Not set
Research Site, München, Not set
Research Site, Münster, Not set
Research Site, Wiesbaden, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Miskolc, Not set
Research Site, Nyíregyháza, Not set
Research Site, Zalaegerszeg, Not set
Research Site, Bangalore, Not set
Research Site, Jaipur, Not set
Research Site, Kolkata, Not set
Research Site, Nagpur, Not set
Research Site, Nashik, Not set
Research Site, New Delhi, Not set
Research Site, Pondicherry, Not set
Research Site, Vadodara, Not set
Research Site, Borgo San Lorenzo, Not set
Research Site, Catanzaro, Not set
Research Site, Genova, Not set
Research Site, Livorno, Not set
Research Site, Macerata, Not set
Research Site, Milano, Not set
Research Site, Milan, Not set
Research Site, Modena, Not set
Research Site, Napoli, Not set
Research Site, Roma, Not set
Research Site, Rozzano, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukushima-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Isehara-shi, Not set
Research Site, Kagoshima-shi, Not set
Research Site, Kashiwa, Not set
Research Site, Kitaadachi-gun, Not set
Research Site, Koto-ku, Not set
Research Site, Kyoto-shi, Not set
Research Site, Matsuyama-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Niigata-shi, Not set
Research Site, Nishinomiya-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Shinagawa-ku, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Tsukuba, Not set
Research Site, Yokohama-shi, Not set
Research Site, Busan-si, Not set
Research Site, Daegu, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, CD Mexico, Not set
Research Site, Guadalajara Jalisco, Not set
Research Site, Guadalajara, Not set
Research Site, Mexico City, Not set
Research Site, Mexico, Not set
Research Site, Mexico, Not set
Research Site, Bacolod, Not set
Research Site, Cebu City, Not set
Research Site, Cebu, Not set
Research Site, Iloilo City, Not set
Research Site, Muntinlupa City, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, San Juan, Not set
Research Site, Białystok, Not set
Research Site, Bydgoszcz, Not set
Research Site, Skórzewo, Not set
Research Site, Warszawa, Not set
Research Site, Wroclaw, Not set
Research Site, Łódź, Not set
Research Site, Bukit Merah, Not set
Research Site, Singapore, Not set
Research Site, Singapore, Not set
Research Site, Cape Town, Not set
Research Site, Johannesburg, Not set
Research Site, Pretoria, Not set
Research Site, Pretoria, Not set
Research Site, Soweto, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Granada, Not set
Research Site, L'Hospitalet de Llobregat, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Málaga, Not set
Research Site, Santiago de Compostela, Not set
Research Site, Sevilla, Not set
Research Site, Hsinchu, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Tainan, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Chiang Mai, Not set
Research Site, Dusit, Not set
Research Site, Hat Yai, Not set
Research Site, Khon Kaen, Not set
Research Site, Ankara, Not set
Research Site, Ankara, Not set
Research Site, Diyarbakir, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Konya, Not set
Research Site, Malatya, Not set
Research Site, Bristol, Not set
Research Site, Cardiff, Not set
Research Site, Edinburgh, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Northampton, Not set
Research Site, Nottingham, Not set
Research Site, Warwick, Not set
Conditions: Breast Cancer
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Active Not Recruiting
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Canberra Hospital, Garran, Not set +94 locations
Canberra Hospital, Garran, Not set
Calvary Mater Newcastle, Waratah, Not set
Princess Margaret Cancer Centre, Toronto, Not set
CHU d'Amiens - Hôpital Sud, Amiens, Not set
Clinique de l'Europe, Amiens, Not set
ICO Paul Papin, Angers, Not set
Centre Hospitalier d'Auxerre, Auxerre, Not set
Institut Sainte Catherine, Avignon, Not set
CH Simone Veil de Beauvais, Beauvais, Not set
CHRU Jean Minjoz, Besançon, Not set
Institut Bergonié, Bordeaux, Not set
CHU Brest, Brest, Not set
Centre François Baclesse, Caen, Not set
Centre Hospitalier William Morey, Chalon-sur-Saône, Not set
ROC 37, Chambray-lès-Tours, Not set
Centre Jean Perrin, Clermont-Ferrand, Not set
GHPSO, Creil, Not set
Centre Hospitalier Intercommunal de Créteil, Créteil, Not set
Centre Georges François Leclerc, Dijon, Not set
CHU de Dijon, Dijon, Not set
Clinique Victor Hugo, Le Mans, Not set
Centre Oscar Lambret, Lille, Not set
Centre Hospitalier Lyon Sud, Lyon, Not set
Centre Léon Bérard, Lyon, Not set
APHM - Hôpital de la Timone, Marseille, Not set
Institut Paoli Calmettes, Marseille, Not set
Hôpital Saint-Joseph, Marseille, Not set
Hôpital de Mont-de-Marsan, Mont de Marsan, Not set
ICM Val d'Aurelle, Montpellier, Not set
Centre Azuréen de Cancérologie, Mougins, Not set
Médipôle de NANCY SAS, Nancy, Not set
Hôpital Privé du Confluent S.A.S., Nantes, Not set
Centre Antoine Lacassagne, Nice, Not set
Institut de cancérologie du gard, Nîmes, Not set
CHU d'ORLEANS, Orléans, Not set
Institut Curie, Paris, Not set
AP-HP Hôpital Pitié-Salpêtrière, Paris, Not set
Hôpital Cochin, Paris, Not set
Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, Not set
Hôpital Européen Georges Pompidou, Paris, Not set
Institut Mutualiste Montsouris, Paris, Not set
Centre Hospitalier Général de Pau, Pau, Not set
Centre CARIO - HPCA, Plérin, Not set
CHU de Poitiers - Hôpital de la Milétrie, Poitiers, Not set
CHI de Cornouaille, Quimper, Not set
Institut Jean Godinot, Reims, Not set
Centre Eugène Marquis, Rennes, Not set
Centre Henri Becquerel, Rouen, Not set
Centre Hospitalier Privé de Saint-Grégoire, Saint-Grégoire, Not set
ICO - Centre René Gauducheau, Saint-Herblain, Not set
CHU Saint-Etienne - Pôle de Cancérologie, Saint-Étienne, Not set
Institut de Cancérologie de Strasbourg Europe - ICANS, Strasbourg, Not set
Institut Claudius Régaud, Toulouse, Not set
CHU Bretonneau, Tours, Not set
ICL - Centre Alexis Vautrin, Vandœuvre-lès-Nancy, Not set
Institut Gustave Roussy, Villejuif, Not set
Ospedale degli Infermi, Biella, Not set
Spedali Civili-Università di Brescia, Brescia, Not set
Ospedale Civile degli Infermi, Faenza, Not set
Ospedale "Umberto I", Lugo, Not set
IRCCS Ospedale San Raffaele, Milano, Not set
Istituto Europeo di Oncologia, Milano, Not set
Ospedale "Santa Maria delle Croci", Ravenna, Not set
Azienda Sanitaria Universitaria Friuli Centrale, Udine, Not set
Ehime University Hospital, Ehime, Not set
Kurume University Hospital, Fukuoka, Not set
Fukushima Medical University Hospital, Fukushima, Not set
The Cancer Institute Hospital Of JFCR, Koto-Ku, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Saitama Medical University International Medical Center, Saitama, Not set
National Cancer Center, Gyeonggi-do, Not set
Seoul National University Bundang Hospital, Gyeonggi-do, Not set
Seoul National University Hospital, Seoul, Not set
Yonsei Medical Center Severance Hospital, Seoul, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Korea University Guro Hospital, Seoul, Not set
Auckland City Hospital, Auckland, Not set
National University Hospital (NUH), Singapore, Not set
National Cancer Centre Singapore (NCCS), Singapore, Not set
Hospital General Universitario de Elche, Elche, Alicante
Hospital Germans Trias i Pujol / ICO Badalona, Badalona, Not set
Hospital Universitario Reina Sofia, Córdoba, Not set
Hospital Universitario de León, León, Not set
Hospital Son Llátzer, Palma De Mallorca, Not set
Hospital Universitario Son Espases, Palma, Not set
Hospital Clínico Universitario Santiago de Compostela, Santiago De Compostela, Not set
Hospital Universitario y Politécnico La Fe, Valencia, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Queen Elizabeth Hospital, Birmingham, Not set
Addenbrooke's Hospital, Cambridge, Not set
Western General Hospital, Edinburgh, Not set
University College London Hospital, London, Not set
Northampton General Hospital NHS Trust, Northampton, Not set
Royal Cornwall Hospital, Truro, Not set
Conditions: Endometrial Cancer
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Active Not Recruiting
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neo... Read More
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by pathological Complete Response (pCR) rate defined by the local pathologist, and 2) pembrolizumab is superior to placebo (both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as determined by the investigator. The study is considered to have met its primary objective if pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Southern Cancer Center, PC ( Site 8003), Daphne, Alabama +243 locations
Southern Cancer Center, PC ( Site 8003), Daphne, Alabama
Cancer Treatment Centers of America at Western Regional Medical Center ( Site 0001), Goodyear, Arizona
Arizona Oncology Associates PC- HOPE ( Site 8008), Tucson, Arizona
Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0079), Los Angeles, California
El Camino Hospital Cancer Center ( Site 0004), Mountain View, California
Stanford Cancer Center ( Site 0072), Palo Alto, California
UC Davis Comprehensive Cancer Center ( Site 0073), Sacramento, California
University of Colorado, Anschutz Cancer Pavilion ( Site 0008), Aurora, Colorado
Baptist MD Anderson Cancer Center ( Site 0014), Jacksonville, Florida
Southeastern Regional Medical Center, Inc. ( Site 0075), Newnan, Georgia
The University of Chicago Medical Center ( Site 0080), Chicago, Illinois
Orchard Healthcare Research Inc. ( Site 0020), Skokie, Illinois
Midwestern Regional Medical Center, Inc. ( Site 0077), Zion, Illinois
Goshen Center for Cancer Care ( Site 0021), Goshen, Indiana
MercyOne Waterloo Cancer Center ( Site 0016), Waterloo, Iowa
James Graham Brown Cancer Center ( Site 0022), Louisville, Kentucky
Maryland Oncology Hematology, P.A. ( Site 8007), Bethesda, Maryland
Massachusetts General Hospital ( Site 0024), Boston, Massachusetts
MGH - North Shore Cancer Center ( Site 0081), Danvers, Massachusetts
MGH Newton-Wellesley Hospital's Vernon Cancer Center ( Site 0082), Newton, Massachusetts
Henry Ford Health System ( Site 0028), Detroit, Michigan
Mayo Clinic and Medical School (Rochester) ( Site 0029), Rochester, Minnesota
St. Vincent Frontier Cancer Center ( Site 0033), Billings, Montana
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0039), Omaha, Nebraska
Holy Name Medical Center ( Site 0041), Teaneck, New Jersey
Weill Cornell Medical College ( Site 0043), New York, New York
CTCA Southwestern ( Site 0074), Tulsa, Oklahoma
OHSU Knight Cancer Institute ( Site 0051), Portland, Oregon
Northwest Cancer Specialists, P.C. ( Site 8000), Tigard, Oregon
Geisinger Medical Center ( Site 0052), Danville, Pennsylvania
Fox Chase Cancer Center ( Site 0078), Philadelphia, Pennsylvania
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0076), Philadelphia, Pennsylvania
Medical University of South Carolina ( Site 0053), Charleston, South Carolina
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000), Nashville, Tennessee
Texas Oncology-Austin Central ( Site 8004), Austin, Texas
Texas Oncology-Dallas Presbyterian Hospital ( Site 8002), Dallas, Texas
Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8009), Dallas, Texas
Texas Oncology-Memorial City ( Site 8012), Houston, Texas
University of Texas-MD Anderson Cancer Center ( Site 0083), Houston, Texas
Texas Oncology- Plano East ( Site 8010), Plano, Texas
Texas Oncology - Northeast Texas ( Site 8006), Tyler, Texas
Bon Secours St. Francis Medical Center Oncology Research ( Site 0064), Midlothian, Virginia
Virginia Oncology Associates ( Site 8001), Norfolk, Virginia
Kadlec Clinic Hematology and Oncology ( Site 0070), Kennewick, Washington
Medical Oncology Associates (Summit Cancer Centers) ( Site 0066), Spokane, Washington
Chris OBrien Lifehouse ( Site 2107), Camperdown, New South Wales
Royal North Shore Hospital ( Site 2100), Sydney, New South Wales
Westmead Hospital ( Site 2101), Sydney, New South Wales
Mater Misericordiae Ltd ( Site 2106), South Brisbane, Queensland
Frankston Hospital ( Site 2103), Frankston, Victoria
Peter MacCallum Cancer Centre ( Site 2102), Melbourne, Victoria
Imelda Ziekenhuis Bonheiden ( Site 0703), Bonheiden, Antwerpen
UZ Antwerpen - Medical Oncology ( Site 0709), Edegem, Antwerpen
Institut Jules Bordet ( Site 0710), Anderlecht, Bruxelles-Capitale, Region De
Cliniques Universitaires Saint-Luc ( Site 0701), Brussels, Bruxelles-Capitale, Region De
CHC MontLegia ( Site 0707), Liège, Liege
Jessa Ziekenhuis Campus Virga Jesse ( Site 0704), Hasselt, Limburg
CHU UCL Namur Site de Godinne ( Site 0706), Yvoir, Namur
AZ Maria Middelares Gent ( Site 0700), Gent, Oost-Vlaanderen
UZ Leuven ( Site 0702), Leuven, Vlaams-Brabant
AZ Groeninge ( Site 0705), Kortrijk, West-Vlaanderen
Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 0205), Goiania, Goias
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0206), Ijui, Rio Grande Do Sul
Associacao Hospitalar Moinhos de Vento ( Site 0201), Porto Alegre, Rio Grande Do Sul
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0202), Porto Alegre, Rio Grande Do Sul
CEPON - Centro de Pesquisas Oncologicas ( Site 0208), Florianopolis, Santa Catarina
Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0207), Itajai, Santa Catarina
Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC3 ( Site 0200), Rio de Janeiro, Not set
Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 0204), Sao Paulo, Not set
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0210), Sao Paulo, Not set
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0209), Sao Paulo, Not set
Cross Cancer Institute ( Site 0115), Edmonton, Alberta
BC Cancer-Vancouver Center ( Site 0116), Vancouver, British Columbia
Princess Margaret Cancer Centre ( Site 0112), Toronto, Ontario
CISSS de la Monteregie-Centre ( Site 0108), Greenfield Park, Quebec
Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0111), Montreal, Quebec
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0114), Montreal, Quebec
Jewish General Hospital ( Site 0103), Montreal, Quebec
Centre Hospitalier Regional de Trois-Rivieres ( Site 0106), Trois-Rivières, Quebec
CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0101), Quebec, Not set
Anhui Provincial Hospital ( Site 3224), Heifei, Anhui
Ruijin Hosp,Shanghai Jiao Tong University School of Medicine ( Site 3215), Shanghai, Anhui
Cancer Hospital Chinese Academy of Medical Sciences ( Site 3208), Beijing, Beijing
Fujian Medical University Union Hospital-1 Bingfanglou-Oncology ( Site 3207), Fuzhou Fujian, Fujian
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 3213), Guangzhou, Guangdong
Fourth Hospital Of Hebei Medical University ( Site 3216), Shijia Zhuang, Hebei
Harbin Medical University Cancer Hospital ( Site 3200), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 3212), Zhengzhou, Henan
Hubei Cancer Hospital ( Site 3211), Wuhan, Hubei
Hunan Cancer Hospital ( Site 3214), Changsha, Hunan
The First Affiliated Hospital of Zhejiang University ( Site 3203), Hangzhou, Jiangsu
The First Hospital of Jilin University ( Site 3201), Changchun, Jilin
Fudan University Shanghai Cancer Center ( Site 3205), Shanghai, Shanghai
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3220), XI An, Shanxi
Tianjin Medical University Cancer Institute & Hospital ( Site 3209), Tianjin, Tianjin
The Affiliated Cancer Hospital of Xinjiang Medical ( Site 3219), Urumqi, Xinjiang
Zhejiang Provincial People's Hospital ( Site 3225), Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 3210), Hangzhou, Zhejiang
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0405), Medellin, Antioquia
Rodrigo Botero SAS ( Site 0407), Medellin, Antioquia
Clinica de la Costa S.A.S. ( Site 0400), Barranquilla, Atlantico
IMAT S.A.S ( Site 0401), Monteria, Cordoba
Centro de Investigacion Clinica del Country ( Site 0402), Bogota, Distrito Capital De Bogota
Fundacion Universitaria Sanitas ( Site 0403), Bogota, Distrito Capital De Bogota
Clínica Imbanaco S.A.S ( Site 0406), Cali, Valle Del Cauca
Hospital Metropolitano - Sede Lindora ( Site 4203), Santa Ana, San Jose
Centre Francois Baclesse ( Site 0927), Caen, Calvados
Centre Georges Francois Leclerc ( Site 0920), Dijon, Cote-d Or
Institut Claudius Regaud IUCT Oncopole ( Site 0903), Toulouse, Haute-Garonne
Institut Curie - Centre Rene Huguenin ( Site 0917), Saint-Cloud, Hauts-de-Seine
Centre de Cancerologie du Grand Montpellier ( Site 0925), Montpellier, Herault
CHR-METZ-THIONVILLE - Hopital de Mercy ( Site 0919), Metz, Moselle
Centre Oscar Lambret ( Site 0911), Lille, Nord-Pas-de-Calais
Institut Sainte Catherine ( Site 0916), Avignon, Provence-Alpes-Cote-d Azur
Centre Jean Perrin ( Site 0909), Clermont Ferrand Cedex, Puy-de-Dome
Clinique Victor Hugo Le Mans ( Site 0906), Le Mans, Sarthe
Institut Gustave Roussy ( Site 0926), Villejuif, Val-de-Marne
Institut Curie ( Site 0900), Paris, Not set
Hopital Saint-Louis ( Site 0908), Paris, Not set
Hopital Tenon ( Site 0914), Paris, Not set
Medizinische Management GmbH ( Site 1012), Friedrichshafen, Baden-Wurttemberg
Universitaetsklinikum Erlangen ( Site 1001), Erlangen, Bayern
Klinikum der Universitaet Muenchen - Grosshadern ( Site 1000), Muenchen, Bayern
Sana Klinikum Offenbach GmbH ( Site 1002), Offenbach, Hessen
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 1004), Wiesbaden, Hessen
MVZ Onko Medical GmbH Hannover ( Site 1013), Hannover, Niedersachsen
Gynaekologisches Zentrum ( Site 1003), Bonn, Nordrhein-Westfalen
Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 1006), Essen, Nordrhein-Westfalen
Frauenklinik St. Louise ( Site 1014), Paderborn., Nordrhein-Westfalen
Caritas Klinikum Saarbruecken St. Theresia ( Site 1009), Saarbruecken, Saarland
Universitaetsklinikum Carl Gustav Carus ( Site 1008), Dresden, Sachsen
MVZ Nordhausen gGmbH - Praxis Dr. Grafe ( Site 1005), Nordhausen, Thuringen
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 2913), Kecskemét, Bacs-Kiskun
Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 2905), Pecs, Baranya
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 2904), Miskolc, Borsod-Abauj-Zemplen
Budapesti Szent Margit Korhaz ( Site 2901), Budapest, Not set
Orszagos Onkologiai Intezet ( Site 2908), Budapest, Not set
Budapesti Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 2902), Budapest, Not set
Debreceni Egyetem Klinikai Kozpont ( Site 2907), Debrecen, Not set
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2915), Kaposvar, Not set
Bon Secours Hospital ( Site 1554), Cork, Not set
St. James s Hospital ( Site 1553), Dublin, Not set
HaEmek Medical Center ( Site 1712), Afula, Not set
Assuta Ashdod Public ( Site 1704), Ashdod, Not set
Soroka Medical Center ( Site 1701), Beer Sheva, Not set
Rambam Health Care Campus-Oncology Division ( Site 1705), Haifa, Not set
Shaare Zedek Medical Center ( Site 1708), Jerusalem, Not set
Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1700), Jerusalem, Not set
Meir Medical Center ( Site 1710), Kfar-Saba, Not set
Holy Family Hospital ( Site 1711), Nazareth, Not set
Rabin Medical Center ( Site 1702), Petah Tikva, Not set
Chaim Sheba Medical Center. ( Site 1707), Ramat Gan, Not set
Kaplan Medical Center ( Site 1703), Rehovot, Not set
Sourasky Medical Center ( Site 1706), Tel Aviv, Not set
Assuta Medical Center ( Site 1709), Tel Aviv, Not set
Aichi Cancer Center ( Site 2601), Nagoya, Aichi
National Cancer Center Hospital East ( Site 2613), Kashiwa, Chiba
National Hospital Organization Hokkaido Cancer Center ( Site 2607), Sapporo, Hokkaido
Hyogo Medical University Hospital ( Site 2600), Nishinomiya, Hyogo
Kitasato University Hospital ( Site 2616), Sagamihara, Kanagawa
Kumamoto University Hospital ( Site 2602), Kumamoto-shi, Kumamoto
Saitama Medical University International Medical Center ( Site 2606), Hidaka, Saitama
Saitama Prefectural Cancer Center ( Site 2612), Kitaadachi-gun, Saitama
Shizuoka Cancer Center ( Site 2611), Suntogun, Shizuoka
Chiba Cancer Center ( Site 2605), Chiba, Not set
Fukushima Medical University Hospital ( Site 2610), Fukushima, Not set
Hiroshima City Hiroshima Citizens Hospital ( Site 2603), Hiroshima, Not set
National Hospital Organization Osaka National Hospital ( Site 2614), Osaka, Not set
Toranomon Hospital ( Site 2608), Tokyo, Not set
Cancer Institute Hospital of JFCR ( Site 2604), Tokyo, Not set
Showa Medical University Hospital ( Site 2615), Tokyo, Not set
National Cancer Center ( Site 2204), Goyang-si, Kyonggi-do
Seoul National University Hospital ( Site 2200), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 2201), Seoul, Not set
Asan Medical Center ( Site 2202), Seoul, Not set
Samsung Medical Center ( Site 2203), Seoul, Not set
Tauranga Hospital ( Site 2302), Tauranga, Bay Of Plenty
Canterbury Regional Cancer & Blood Services ( Site 2303), Christchurch, Canterbury
Capital & Coast District Health Board - Wellington Hospital ( Site 2301), Wellington, Not set
Dolnoslaskie Centrum Onkologii. ( Site 1820), Wrocław, Dolnoslaskie
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1800), Bydgoszcz, Kujawsko-pomorskie
Instytut Centrum Zdrowia Matki Polki ( Site 1821), Lodz, Lodzkie
Mazowiecki Szpital Specjalistyczny im. dr Jozefa Psarskiego ( Site 1814), Ostroleka, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1899), Warszawa, Mazowieckie
Mazowiecki Szpital Onkologiczny ( Site 1803), Wieliszew, Mazowieckie
Bialostockie Centrum Onkologii ( Site 1819), Bialystok, Podlaskie
Wojewodzkie Centrum Onkologii Copernicus ( Site 1817), Gdansk, Pomorskie
Szpitale Pomorskie Sp. z o.o. ( Site 1818), Gdynia, Pomorskie
Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1810), Bielsko-Biala, Slaskie
Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1807), Bytom, Slaskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1801), Gliwice, Slaskie
Fundacao Champalimaud ( Site 2500), Lisboa, Aveiro
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2501), Lisboa, Not set
Unidade Local de Saude de Santo António - Hospital Santo António ( Site 2503), Porto, Not set
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 2502), Porto, Not set
UPR Comprehensive Cancer Center ( Site 6200), San Juan, Not set
Arkhangelsk Clinical Oncological Dispensary ( Site 1901), Arkhangelsk, Arkhangel Skaya Oblast
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1909), Ufa, Baskortostan, Respublika
N.N. Blokhin NMRCO ( Site 1908), Moscow, Moskva
Central Clinical Hospital with outpatient Clinic ( Site 1907), Moscow, Moskva
Medical Rehabilitation Center ( Site 1912), Moscow, Moskva
Ryazan Regional Clinical Oncology Dispensary ( Site 1910), Ryazan, Ryazanskaya Oblast
Railway Hospital of OJSC ( Site 1913), Saint Petersburg, Sankt-Peterburg
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1900), Saint Petersburg, Sankt-Peterburg
Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 1903), Kazan, Tatarstan, Respublika
Tomsk Scientific Research Institute of Oncology ( Site 1905), Tomsk, Tomskaya Oblast
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1363), Hospitalet de Llobregat, Barcelona
Hospital Teresa Herrera - Chuac ( Site 1358), A Coruna, La Coruna
Hospital General Universitario Gregorio Maranon ( Site 1367), Madrid, Madrid, Comunidad De
Hospital Quiron de Madrid ( Site 1351), Pozuelo de Alarcon, Madrid
Hospital Clinico Universitario de Valencia ( Site 1355), Valencia, Valenciana, Comunitat
Instituto Oncologico Baselga.Hospital Quiron. ( Site 1352), Barcelona, Not set
Hospital Vall D Hebron ( Site 1357), Barcelona, Not set
Hospital Clinic I Provincial de Barcelona ( Site 1353), Barcelona, Not set
Complejo Hospitalario de Jaen ( Site 1364), Jaen, Not set
Hospital Beata María Ana-oncology ( Site 1370), Madrid, Not set
Hospital Clinico San Carlos ( Site 1354), Madrid, Not set
Hospital Universitario 12 de Octubre ( Site 1356), Madrid, Not set
Hospital Universitario Virgen del Rocio ( Site 1360), Sevilla, Not set
Hospital General Arnau de Vilanova de Valencia ( Site 1369), Valencia, Not set
China Medical University Hospital ( Site 2401), Taichung, Not set
National Cheng Kung University Hospital ( Site 2400), Tainan, Not set
National Taiwan University Hospital ( Site 2404), Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2403), Taipei, Not set
Linkou Chang Gung Memorial Hospital ( Site 2402), Taoyuan, Not set
MNPE City Clinical Hospital #4 of Dnipro Regional Council ( Site 2702), Dnipro, Dnipropetrovska Oblast
MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700), Kryviy Rih, Dnipropetrovska Oblast
MI Precarpathian Clinical Oncology Center ( Site 2707), Ivano-Frankivsk, Ivano-Frankivska Oblast
Communal non profit enterprise Regional Clinical Oncology Center ( Site 2721), Kharkiv, Kharkivska Oblast
Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council ( Site 2713), Antonivka Village, Khersonska Oblast
Khmelnitskiy Regional Onkology Dispensary ( Site 2704), Khmelnitskiy, Khmelnytska Oblast
SNPE National Cancer Institute ( Site 2719), Kyiv, Kyivska Oblast
MI Odesa Regional Clinical Hospital ( Site 2701), Odesa, Odeska Oblast
MI Odessa Regional Oncological Centre ( Site 2714), Odesa, Odeska Oblast
Medical center of the Limited Liability Company Yulis ( Site 2720), Zaporizhzhia, Zaporizka Oblast
Kyiv City Clinical Oncology Centre ( Site 2716), Kyiv, Not set
University Hospitals Bristol NHS Foundation Trust ( Site 1503), Bristol, Bristol, City Of
Nottingham University Hospitals NHS Trust ( Site 1504), Nottingham, England
Colchester General Hospital ( Site 1508), Colchester, Essex
Barts Health NHS Trust ( Site 1500), London, London, City Of
Guy's Hospital ( Site 1501), London, London, City Of
St. Georges University Hospital NHS Foundation Trust ( Site 1505), London, London, City Of
Birmingham & Solihull Heartlands Hospital NHS ( Site 1506), Solihull, Not set
Royal Cornwall Hospital ( Site 1502), Truro, Not set
Conditions: Breast Cancer
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Recruiting
This first-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, or an anti-huma... Read More
This first-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, or an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor in patients with non-small cell lung cancer (NSCLC).
The trial will comprise of several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above.
The trial will enroll patients with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 9, unresectable NSCLC Stage III in Cohort 5, and resectable NSCLC of Stage II and III in Cohort 6. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Kentucky Chandler Medical Center, Lexington, Kentucky +41 locations
University of Kentucky Chandler Medical Center, Lexington, Kentucky
Norton Cancer Institute, Louisville, Kentucky
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
NEXT Virginia, Fairfax, Virginia
Scientia Clinical Research, Randwick, New South Wales
Cancer Research SA, Adelaide, South Australia
Monash Health, Clayton, Victoria
Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt, Not set
University Medical Center Hamburg-Eppendorf, Hamburg, Not set
Universitätsklinikum Köln, Köln, Not set
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Not set
ICON-PRA Budapest, Fázis 1 Vizsgálóhely, Budapest, Not set
Semmelweis Egyetem ÁOK Belgyógyászati és Onkológiai Klinika, Budapest, Not set
National Institute of Oncology, Budapest, Not set
Clinexpert Ltd, Gyongyos, Not set
Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set
Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, Not set
NZOZ Medpolonia Sp. Z o.o, Poznań, Not set
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warsaw, Not set
Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol, Badalona, Not set
Hospital Universitario Vall d'Hebron, Barcelona, Not set
MD Anderson Cancer Center, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Not set
Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Hospital Clinico Universitario (University Clinical Hospital), Santiago De Compostela, Not set
Hospital Universitario Virgen Macarena, Sevilla, Not set
Hospital Universitario y Politecnico La Fe, Valencia, Not set
Adana Sehir Hospital, Adana, Not set
Haceteppe Hospital, Ankara, Not set
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Not set
Ankara City Hospital, Ankara, Not set
Koc University Hospital, Istanbul, Not set
University Medical Faculty Oncology Institute, Istanbul, Not set
Yeditepe University, Istanbul, Not set
Ege University School of Medicine Tulay Aktas Oncology Hospital, Izmir, Not set
Dokuz Eylul Medical School, İzmir, Not set
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Not set
Velindre NHS Trust, Cardiff, Not set
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set
Guy's and St Thomas NHS Foundation Trust, London, Not set
University College London Hospitals NHS Foundation Trust, London, Not set
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Not set
Conditions: Non-Small Cell Lung Cancer
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Active Not Recruiting
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: The University of Arizona Cancer Center, Tucson, Arizona +83 locations
The University of Arizona Cancer Center, Tucson, Arizona
City of Hope National Medical Center, Duarte, California
UC Davis Comprehensive Cancer Center, Sacramento, California
Sansum Clinic, Santa Barbara, California
Rocky Mountain Cancer Center, Denver, Colorado
Ochsner Clinic, New Orleans, Louisiana
Maryland Oncology Hematology, P.A., Columbia, Maryland
Mayo Clinic, Rochester, Minnesota
Texas Oncology, Austin, Texas
Baylor Scott and White Research Institute, Dallas, Texas
Renovatio Clinical Consultants Llc, The Woodlands, Texas
Texas Oncology-Wichita Falls Texoma Cancer Center, Wichita Falls, Texas
Virginia Cancer Specialists, Pc, Arlington, Virginia
Blue Ridge Cancer Care, Roanoke, Virginia
Princess Alexandra Hospital Australia, Woolloongabba, Queensland
Flinders Medical Centre, Bedford Park, South Australia
Monash Medical Centre Clayton, Clayton, Victoria
Zna Middelheim, Antwerpen, Not set
Ulb Hospital Erasme, Bruxelles, Not set
Herlev Og Gentofte Hospital, Herlev, Not set
Vejle Hospital, Vejle, Not set
Institut de Cancerologie de L Ouest - Site Paul Papin, Angers Cedex 2, Not set
Chu Besancon Hospital Jean Minjoz, Besançon, Not set
Centre Hospitalier Universitaire de Bordeaux, Bordeaux Cedex, Not set
Centre Leon Berard, Lyon, Not set
Chu Hopital de La Timone, Marseille Cedex 5, Not set
Institut Du Cancer de Montpellier, Montpellier, Not set
Centre Antoine Laccassagne, Nice, Not set
Hospital Universitaire Pitie-Salpetriere, Paris Cedex 13, Not set
Hospital de La Miletrie, Poitiers Cedex, Not set
Chu de Rennes - Hospital Pontchaillou, Rennes Cedex 09, Not set
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, Not set
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau, Saint Herblain, Not set
Institut de Cancerologie de Strasbourg, Strasbourg, Not set
Chu Toulouse Hopital Rangueil, Toulouse Cedex 9, Not set
Institut Gustave Roussy, Villejuif Cedex, Not set
Universitatsklinikum Bonn Aoer, Bonn, Not set
University Clinic Carl Gustav Carus Technical University Dresden, Dresden, Not set
Asklepios Klinik Altona, Hamburg, Not set
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano, Milano, Not set
European Institute of Oncology, Milano, Not set
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Not set
Fondazione Irccs Ca Granda Ospedale Maggiore, Milan, Not set
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Not set
University Di Cagliari-Presidio Policlinico Monserrato, Monserrato, Not set
Azienda Ospedaliera Universitaria University Degli Studi Della Campania Luigi Vanvitelli, Napoli, Not set
Iov - Istituto Oncologico Veneto Irccs, Padova, Not set
Azienda Ospedaliero Universitaria Pisana, Pisa, Not set
Ospedale Degli Infermi, Rimini, Not set
I.R.C.C.S. Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Not set
Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette, Not set
National Cancer Center Hospital, Chuo-ku, Not set
Kyushu University Hospital, Fukuoka-shi, Not set
Saitama Medical University International Medical Center, Hidaka-shi, Not set
Aichi Cancer Center Hospital, Nagoya-shi, Not set
Osaka International Cancer Institute, Osaka-shi, Not set
Tohoku University Hospital, Sendai-shi, Not set
Center Hospital of the National Center For Global Health and Medicine, Shinjuku-ku, Not set
Haukeland University Hospital, Bergen, Not set
Oslo Universitetssykehus, Oslo, Not set
Panoncology Trials Pan American Center For Oncology Trials, Llc, San Juan, Not set
Complejo Hospitalario Universitario A Coruna, A Coruña, Not set
Hospital General Universitario Vall D Hebron, Barcelona, Not set
Hospital Clinic de Barcelona, Barcelona, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Universitario de La Paz, Madrid, Not set
Son Espases University Hospital, Palma de Mallorca, Not set
Hospital Universitario Virgen Del Rocio, Sevilla, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Sahlgrenska University Hospital, Goteborg, Not set
Skaenes Universitetssjukhus Lund, Lund, Not set
Stockholm South General Hospital Sodersjukhuset, Stockholm, Not set
Royal Sussex County Hospital, Brighton, Not set
Addenbrooke'S Hospital, Cambridge, Not set
Royal Surrey County Hospital, Guildford, Not set
Castle Hill Hospital, Hull, Not set
Leeds Teaching Hospital, Leeds, Not set
Royal Free London Nhs Foundation Trust, London, Not set
The Royal Marsden Nhs Foundation Trust - Chelsea, London, Not set
The Christie Nhs Foundation Trust Uk, Manchester, Not set
Churchill Hospital, Oxford, Not set
Royal Preston Hospital, Preston, Not set
The Royal Marsden Nhs Foundation Trust - Sutton, Sutton, Not set
Royal Cornwall Hospital Truro Sunrise Centre, Truro, Not set
Conditions: Squamous Cell Carcinoma of the Anal Canal
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Active Not Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements). Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Phoenix, Arizona +255 locations
Research Site, Phoenix, Arizona
Research Site, Tucson, Arizona
Research Site, Hot Springs National Park, Arkansas
Research Site, Little Rock, Arkansas
Research Site, Springdale, Arkansas
Research Site, Fountain Valley, California
Research Site, Los Angeles, California
Research Site, Orange, California
Research Site, Boulder, Colorado
Research Site, Fort Myers, Florida
Research Site, Jacksonville, Florida
Research Site, Lakeland, Florida
Research Site, Saint Petersburg, Florida
Research Site, West Palm Beach, Florida
Research Site, Hinsdale, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Bettendorf, Iowa
Research Site, Des Moines, Iowa
Research Site, Iowa City, Iowa
Research Site, Baton Rouge, Louisiana
Research Site, Covington, Louisiana
Research Site, Duluth, Minnesota
Research Site, Rochester, Minnesota
Research Site, Hannibal, Missouri
Research Site, Lincoln, Nebraska
Research Site, Lincoln, Nebraska
Research Site, Clifton Park, New York
Research Site, Asheville, North Carolina
Research Site, Canton, Ohio
Research Site, Columbus, Ohio
Research Site, Maumee, Ohio
Research Site, Tulsa, Oklahoma
Research Site, Portland, Oregon
Research Site, Salem, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, York, Pennsylvania
Research Site, Watertown, South Dakota
Research Site, Memphis, Tennessee
Research Site, Dallas, Texas
Research Site, Fort Worth, Texas
Research Site, Houston, Texas
Research Site, Houston, Texas
Research Site, Irving, Texas
Research Site, Fairfax, Virginia
Research Site, Henrico, Virginia
Research Site, Norfolk, Virginia
Research Site, Renton, Washington
Research Site, Spokane, Washington
Research Site, Tacoma, Washington
Research Site, Appleton, Wisconsin
Research Site, La Crosse, Wisconsin
Research Site, Graz, Not set
Research Site, Rankweil, Not set
Research Site, Wien, Not set
Research Site, Wien, Not set
Research Site, Blumenau, Not set
Research Site, Florianópolis, Not set
Research Site, Fortaleza, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Taubaté, Not set
Research Site, Vitoria, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Saint John, New Brunswick
Research Site, Brampton, Ontario
Research Site, Kitchener, Ontario
Research Site, Newmarket, Ontario
Research Site, Sudbury, Ontario
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, St-Jerome, Quebec
Research Site, Saskatoon, Saskatchewan
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Kunming, Not set
Research Site, Lanzhou, Not set
Research Site, Liuzhou, Not set
Research Site, Shandong, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shantou, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Wuhan, Not set
Research Site, Xiamen, Not set
Research Site, Yangzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Brest, Not set
Research Site, Creteil, Not set
Research Site, Gleize, Not set
Research Site, Montpellier, Not set
Research Site, Nimes, Not set
Research Site, Paris CEDEX 14, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint-Quentin, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Toulon Cedex 9, Not set
Research Site, Toulouse, Not set
Research Site, Tours, Not set
Research Site, Bad Berka, Not set
Research Site, Berlin, Not set
Research Site, Frankfurt A. Main, Not set
Research Site, Gauting, Not set
Research Site, Gütersloh, Not set
Research Site, Hamburg, Not set
Research Site, Kassel, Not set
Research Site, Kiel, Not set
Research Site, Koblenz, Not set
Research Site, Minden, Not set
Research Site, Rosenheim, Not set
Research Site, Velbert, Not set
Research Site, Würzburg, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Peiraias, Not set
Research Site, Thessaloniki, Not set
Research Site, Thessaloniki, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Gyöngyös - Mátraháza, Not set
Research Site, Kaposvár, Not set
Research Site, Pécs, Not set
Research Site, Szekszárd, Not set
Research Site, Szolnok, Not set
Research Site, Törökbálint, Not set
Research Site, Calicut, Not set
Research Site, Delhi, Not set
Research Site, Delhi, Not set
Research Site, Jaipur, Not set
Research Site, Kolkata, Not set
Research Site, Madurai, Not set
Research Site, Puducherry, Not set
Research Site, Firenze, Not set
Research Site, Lecco, Not set
Research Site, Messina, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Peschiera Del Garda, Not set
Research Site, Rozzano, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hidaka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Wakayama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Busan, Not set
Research Site, Cheongju-si, Not set
Research Site, Jinju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon-si, Not set
Research Site, Suwon, Not set
Research Site, Cdmx, Not set
Research Site, Del. Cuauhtemoc, Not set
Research Site, Mexico, Not set
Research Site, San Luis Potosí, Not set
Research Site, Arequipa, Not set
Research Site, Concepción, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Grudziądz, Not set
Research Site, Kielce, Not set
Research Site, Koszalin, Not set
Research Site, Olsztyn, Not set
Research Site, Poznań, Not set
Research Site, Przemysl, Not set
Research Site, Racibórz, Not set
Research Site, Radom, Not set
Research Site, Siedlce, Not set
Research Site, Las Palmas de Gran Canaria, Not set
Research Site, Lugo, Not set
Research Site, Madrid, Not set
Research Site, Santander, Not set
Research Site, Sevilla, Not set
Research Site, Valencia, Not set
Research Site, Zaragoza, Not set
Research Site, Gävle, Not set
Research Site, Linköping, Not set
Research Site, Lund, Not set
Research Site, Stockholm, Not set
Research Site, Uppsala, Not set
Research Site, Hsinchu, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan City, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Aberdeen, Not set
Research Site, Cambridge, Not set
Research Site, Cardiff, Not set
Research Site, Cheltenham, Not set
Research Site, Edinburgh, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Middlesborough, Not set
Research Site, Newcastle-Upon-Tyne, Not set
Research Site, Taunton, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh city, Not set
Research Site, Ho Chi Minh, Not set
Conditions: NSCLC
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Active Not Recruiting
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: City of Hope National Medical Center, Duarte, California +178 locations
City of Hope National Medical Center, Duarte, California
Can Care Assoc Med Group Inc, Redondo Beach, California
Univ of Calif, San Francisco, San Francisco, California
Central Coast Medical Oncology, San Luis Obispo, California
UCLA Oncology Office, Santa Monica, California
Stanford Cancer Institute, Stanford, California
Kaiser Permanente - Walnut Creek, Walnut Creek, California
Univ of Colorado Canc Ctr, Aurora, Colorado
University of Colorado, Aurora, Colorado
Rocky Mountain Cancer Center - Denver, Denver, Colorado
Christina Care Institutional Review Board, Newark, Delaware
Florida Cancer Specialists, Fort Myers, Florida
Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida
Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building), Saint Petersburg, Florida
Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa, Florida
Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia
Kootenai Cancer Center, Post Falls, Idaho
Loyola University Med Center, Maywood, Illinois
Illinois Cancer Care, Peoria, Illinois
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Hematology-Oncology, Bettendorf, Iowa
Oncology Assoc of Cedar Rapids, Cedar Rapids, Iowa
Anne Arundel Medical Center, Annapolis, Maryland
Johns Hopkins Univ Med Center, Baltimore, Maryland
Massachusetts General Hospital, Boston, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts
Karmanos Cancer Institute, Detroit, Michigan
Minnesota Oncology Hematology, Pa, Minneapolis, Minnesota
University of Minnesota., Minneapolis, Minnesota
Mayo Clinic - Rochester, Rochester, Minnesota
St. John's Mercy Medical Ctr, Saint Louis, Missouri
Mercy Clinic Cancer & Hematology, Springfield, Missouri
Comp Cancer Centers of Nevada, Las Vegas, Nevada
St. Barnabas Health Care Sys, Livingston, New Jersey
Clinical Research Alliance, Lake Success, New York
NS-Long Island Jewish Hlth Sys, Lake Success, New York
Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York
Memorial Sloan-Kettering Cancer Center, New York, New York
Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina
The Mark H. Zangmeister Ctr, Columbus, Ohio
Northwest Cancer Specialists - Portland (N Broadway), Portland, Oregon
Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee
Texas Oncology, Bedford, Texas
Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas
USO, Plano, Texas
Cancer Therapy & Research Center, San Antonio, Texas
USO - Tyler Cancer Ctr, Tyler, Texas
Uni of Washington Medical Center, Seattle, Washington
Univ of WA Medical Center, Seattle, Washington
Northwest Medical Specialties, Tacoma, Washington
Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria
Peter MacCallum Cancer Center, Melbourne, Victoria
UZ Gent, Gent, Not set
ZAS Sint Augustinus Wilrijk, Pharmacy, Wilrijk, Not set
Clinica de Oncologia de Porto Alegre - CliniOnco, Porto Alegre, Rio Grande Do Sul
Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul
Clinica de Neoplasias Litoral, Itajai, Santa Catarina
Faculdade de Medicina do ABC - FMABC, Santo Andre, São Paulo
Hospital Perola Byington, Sao Paulo, São Paulo
Instituto Nacional de Cancer - INCa, Rio de Janeiro, Not set
Complex Oncology Center - Plovdiv First Internal Chemotherapy Department, Plovdiv, Not set
SHATO - Sofia, Sofia, Not set
BC Cancer ? Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna, British Columbia
Ottawa Regional Cancer Centre, Ottawa, Ontario
Saskatoon Cancer Centre, Saskatoon, Saskatchewan
CHU de Québec ? Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Not set
Fundacion Arturo Lopez Perez, Santiago, Not set
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, Not set
Beijing Cancer Hospital, Beijing, Not set
the First Hospital of Jilin University, Changchun, Not set
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou City, Not set
Sun Yet-sen University Cancer Center, Guangzhou, Not set
Zhejiang Provincial People's Hospital, Hangzhou, Not set
Zhejiang Cancer Hospital, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, Not set
Jiangsu Cancer Hospital, Nanjing City, Not set
Fudan University Shanghai Cancer Center, Shanghai City, Not set
Fakultni nemocnice Olomouc, Olomouc, Not set
Fakultni Poliklinika Vseobecne Fakultni Niemocnice, Praha 2, Not set
Odense Universitetshospital, Onkologisk Afdeling R, Odense, Not set
Vejle Sygehus, Vejle, Not set
Centre Francois Baclesse, Caen, Not set
Centre Georges Francois Leclerc, Dijon, Not set
Institut Paoli Calmettes, Marseille, Not set
Institut régional du Cancer Montpellier, Montpellier, Not set
Hopital Tenon, Paris, Not set
Institut Curie, Paris, Not set
Ico Rene Gauducheau, Saint Herblain, Not set
Institut Curie - Hopital Rene Huguenin, Saint-Cloud, Not set
Studienzentrum Aschaffenburg, Aschaffenburg, Not set
Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche, Berlin, Not set
HELIOS Klinikum Berlin-Buch, Berlin, Not set
Rotkreuzklinikum München, Muenchen, Not set
Klinikum der Universität München, Muenchen, Not set
Grupo Angeles, Guatemala City, Not set
Queen Mary Hospital, Hong Kong, Not set
Szent Margit Hospital, Budapest, Not set
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Not set
Markusovszky Hospital, Szombathely, Not set
Shaare Zedek Medical Center, Jerusalem, Not set
Tel Aviv Sourasky Medical Ctr, Tel Aviv, Not set
Ospedale San Carlo, Potenza, Basilicata
Campus Universitario S.Venuta, Catanzaro, Calabria
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE, Napoli, Campania
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola, Meldola, Emilia-Romagna
Ospedale Regionale Di Parma, Parma, Emilia-Romagna
RCCS - Centro di Riferimento, Aviano (PN), Friuli-Venezia Giulia
Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia
Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia
Istituto Europeo Di Oncologia, Milano, Lombardia
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo, Candiolo, Piemonte
Ospedale Civile, Sassari, Sardegna
Humanitas Istituto Clinico Catanese S.p.A, Misterbianco (CT), Sicilia
Hiroshima University Hospital, Hiroshima, Not set
Hyogo Cancer Center, Hyogo, Not set
Kyungpook National University Medical Center, Daegu, Not set
National Cancer Center, Gyeonggi-do, Not set
Gachon University Gil Medical Center, Incheon, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Asan Medical Center, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Centro de Investigacion, Acapulco, Guerrero
Instituto Nacional de Cancer, D.f., Mexico CITY (federal District)
Consultorio de Medicina Especializada, Distrito Federal, Not set
Auckland city hospital, Auckland, Not set
Private Health Organization Acibadem Sistina Hospital, Skopje, Not set
Oslo Universitetssykehus HF, Oslo, Not set
The Panama Clinic, Panama City, Not set
Instituto Nacional de Enfermedades Neoplasicas, Lima, Not set
Instituto, Lima, Not set
Cebu Cancer Institute, Cebu City, Not set
Veterans Memorial Medical Ctr, Quezon City, Not set
Cardinal Santos Medical Center, San Juan, Not set
Uniwersyteckie Centrum Kliniczne, Gdansk, Not set
?wi?tokrzyskie Centrum Onkologii, Kielce, Not set
Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Not set
Wielkopolskie Centrum Onkologii, Poznan, Not set
Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, Not set
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie, Warszawa, Not set
Hospital da Luz, Lisboa, Not set
Bashkirian Republican Clinical Oncology Dispensary, UFA, Baskortostan
SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Baskortostan
City Clinical Oncology Hospital, Moscow, Moskovskaja Oblast
Blokhin Cancer Research Center, Moskva, Moskovskaja Oblast
FSBI?National Medical Research Center of Oncology named after N.N.Petrov? MHRF, ST Petersburg, Sankt Petersburg
City Oncology Dispensary, St Petersburg, Sankt Petersburg
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Not set
Institute of Oncology Ljubljana, Ljubljana, Not set
Hospital General Universitario de Elche, Elche, Alicante
Hospital de Jerez de la Frontera, Jerez de La Frontera, Cadiz
Hospital de Donostia, San Sebastian, Guipuzcoa
Hospital del Mar, Barcelona, Not set
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set
Hospital Duran i Reynals, Barcelona, Not set
Hospital San Pedro De Alcantara, Caceres, Not set
Hospital Universitari Arnau de Vilanova de Lleida, Lerida, Not set
Hospital General Universitario Gregorio Marañon, Madrid, Not set
Hospital Ramon y Cajal, Madrid, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Universitätsspital Zürich, Zürich, Not set
Chi-Mei Medical Center, Tainan, Not set
National Taiwan Uni Hospital, Taipei, Not set
Bumrungrad International Hosp, Bangkok, Not set
Rajavithi Hospital, Bangkok, Not set
Ninewells Hospital, Dundee, Not set
Western General Hospital, Edinburgh, Not set
Diana Princess of Wales Hosp., Grimsby, Not set
Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, Not set
Royal Free Hospital, London, Not set
Christie Hospital NHS Trust, Manchester, Not set
Mount Vernon Hospital, Middlesex, Not set
Nottingham City Hospital, Nottingham, Not set
Poole General Hospital, Poole, Not set
Queen's Hospital, Romford, Not set
Abertawe and Bro Morgannwg NHS Trust, Swansea, Not set
Royal Cornwall Hospital, Truro, Not set
Conditions: Neoplasm Metastasis
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Active Not Recruiting
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mut... Read More
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions. Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/27/2025
Locations: Research Site, Bonita Springs, Florida +68 locations
Research Site, Bonita Springs, Florida
Research Site, Saint Petersburg, Florida
Research Site, Tallahassee, Florida
Research Site, West Palm Beach, Florida
Research Site, Kansas City, Missouri
Research Site, Bethlehem, Pennsylvania
Research Site, Chattanooga, Tennessee
Research Site, Nashville, Tennessee
Research Site, Houston, Texas
Research Site, Aalst, Not set
Research Site, Leuven, Not set
Research Site, Roeselare, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Debrecen, Not set
Research Site, Deszk, Not set
Research Site, Farkasgyepü, Not set
Research Site, Törökbálint, Not set
Research Site, Ahmedabad, Not set
Research Site, Ahmedabad, Not set
Research Site, Jamnagar, Not set
Research Site, Kochi, Not set
Research Site, Mysuru, Not set
Research Site, Nashik, Not set
Research Site, Nashik, Not set
Research Site, Nashik, Not set
Research Site, Pune, Not set
Research Site, Thiruvananthapuram, Not set
Research Site, Chuo-ku, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kurume-shi,, Not set
Research Site, Matsuyama-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Ube-shi, Not set
Research Site, Dongjakgu, Not set
Research Site, Goyang-si, Not set
Research Site, Seodaemun-gu, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suweonsi Paldalgu, Not set
Research Site, Chihuahua, Not set
Research Site, Culiacan, Not set
Research Site, San Luis Potosí, Not set
Research Site, Blaricum, Not set
Research Site, Harderwijk, Not set
Research Site, Tilburg, Not set
Research Site, Białystok, Not set
Research Site, Poznan, Not set
Research Site, Prabuty, Not set
Research Site, Łódź, Not set
Research Site, Arkhangelsk, Not set
Research Site, Chelyabinsk, Not set
Research Site, Kursk, Not set
Research Site, Moscow, Not set
Research Site, Nal'chik, Not set
Research Site, P. Herzen Moscow Oncology Rese, Not set
Research Site, Sochi, Not set
Research Site, St. Petersburg, Not set
Research Site, Yaroslavl, Not set
Research Site, Dnipro, Not set
Research Site, Kharkiv Region, Not set
Research Site, Kirovohrad, Not set
Research Site, Odesa, Not set
Research Site, Uzhhorod, Not set
Research Site, Zaporizhzhia, Not set
Research Site, Dundee, Not set
Research Site, Hull, Not set
Conditions: Non-small Cell Lung Cancer NSCLC
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Active Not Recruiting
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer Read Less
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
06/24/2025
Locations: Research Site, Tucson, Arizona +31 locations
Research Site, Tucson, Arizona
Research Site, Columbia, Maryland
Research Site, Boston, Massachusetts
Research Site, Boston, Massachusetts
Research Site, Grand Rapids, Michigan
Research Site, Saint Louis, Missouri
Research Site, Dallas, Texas
Research Site, Williamsburg, Virginia
Research Site, Kelowna, British Columbia
Research Site, London, Ontario
Research Site, Greenfield Park, Quebec
Research Site, Montreal, Quebec
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Gdańsk, Not set
Research Site, Kraków, Not set
Research Site, Lublin, Not set
Research Site, Opole, Not set
Research Site, Rzeszów, Not set
Research Site, Warszawa, Not set
Research Site, Warszawa, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Cambridge, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Oxford, Not set
Conditions: Triple Negative Breast Neoplasms
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).
The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).
The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS). Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +170 locations
University of Arkansas for Medical Sciences, Little Rock, Arkansas
City of Hope, Duarte, California
UC San Diego Medical Center, La Jolla, California
Stanford Women's Cancer Center, Palo Alto, California
Kaiser Permanente Medical Center, Vallejo, California
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado
Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford, Connecticut
Yale University School of Medicine, New Haven, Connecticut
Florida Cancer Specialists, Fort Myers, Florida
University of Florida, Gainesville, Florida
Baptist MD Anderson Cancer Center, Jacksonville, Florida
Tampa General Hospital (Cancer Institute), Tampa, Florida
Winship Cancer Institute, Emory University, Atlanta, Georgia
Lewis Cancer & Research Pavilion at St. Joseph's/Candler Health System, Savannah, Georgia
Northwestern Memorial Hospital, Chicago, Illinois
University of Chicago Medical Center, Chicago, Illinois
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Baptist Health Lexington, Lexington, Kentucky
Norton Cancer Institute, Louisville, Kentucky
Women's Cancer Care, Covington, Louisiana
Ochsner Clinic Foundation, New Orleans, Louisiana
Greater Baltimore Medical Center, Baltimore, Maryland
Tufts Medical Center, Boston, Massachusetts
Massachusetts General Hospital, Boston, Massachusetts
Baystate Medical Center, Springfield, Massachusetts
West Michigan Cancer Center, Kalamazoo, Michigan
M Health Fairview University of Minnesota Medical Center - East Bank Hospital, Minneapolis, Minnesota
Metro Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park, Minnesota
MidAmerica Division, Inc. c/o Research Medical Center, Kansas City, Missouri
Rutgers Cancer Institute, New Brunswick, New Jersey
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Roswell Park Cancer Institute, Buffalo, New York
Northwell Health Cancer Institute, Lake Success, New York
Columbia University Medical Center, Herbert Irving Pavilion, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
SUNY Upstate Medical University, Syracuse, New York
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Cleveland Clinic, Cleveland, Ohio
Ohio Health Research Institute, Columbus, Ohio
Oklahoma Cancer Specialists and Research Institute - OCSRI - Tulsa, Tulsa, Oklahoma
Providence Cancer Institute Franz Clinic, Portland, Oregon
Alliance Cancer Specialists, PC, Horsham, Pennsylvania
University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
MUSC Hollings Cancer Center, Charleston, South Carolina
SCRI Oncology Partners, Nashville, Tennessee
University of Texas Southwestern Medical Center, Dallas, Texas
Texas Oncology, Fort Worth, Texas
Baylor College of Medicine Medical Center, Houston, Texas
University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia
Virginia Oncology Associates, Norfolk, Virginia
Fred Hutchinson Cancer Center, Seattle, Washington
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Froedtert and the Medical College of Wisconsin (MCW), Milwaukee, Wisconsin
Chris O'Brien Lifehouse, Camperdown, New South Wales
Mater Cancer Care Centre, South Brisbane, Queensland
Monash Health, Clayton, Victoria
Peter MacCallum Cancer Centre, Melbourne, Victoria
Sir Charles Gairdner Hospital, Murdoch, Western Australia
Clínica de Neoplasias Litoral, Itajai, Not set
Ensino e Terapia de Inovação Clínica AMO - ETICA, Salvador, Not set
London Health Sciences Centre, London, Not set
McGill University Health Centre - Glen Site, Montreal, Not set
CIC-CHU de Québec-Université Laval- Hôpital de l'Enfant-Jésus, Quebec, Not set
Sunnybrook Research Institute, Toronto, Not set
Princess Margaret Cancer Centre, Toronto, Not set
Beijing Cancer Hospital, Beijing, Not set
The First Hospital of Jilin University, Changchun, Not set
Hunan Cancer Hospital, Changsha, Not set
West China Second Hospital of Sichuan University, Chengdu, Not set
Chongqing University Cancer Hospital, Chongqing, Not set
Guangxi Medical University Affiliated Tumor Hospital, Guangxi Zhuang Autonomous Region, Not set
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Not set
Women's Hospital School Of Medicine Zhejiang University, Hangzhou, Not set
Zhejiang Cancer Hospital, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Jiangxi Maternal and Child Health Hospital, Nanchang, Not set
Fudan University Shanghai Cancer Center, Shanghai, Not set
Shanghai Tenth People's Hospital, Shanghai, Not set
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Not set
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Not set
The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Not set
Henan Cancer Hospital, Zhengzhou, Not set
Nemocnice AGEL, Nový Jičín a.s., Nový Jičín, Not set
General University Hospital in Prague, Prague, Not set
University Hospital Bulovka, Prague, Not set
Centre Francois Baclesse, Caen Cedex 5, Not set
Institut Paoli Calmettes, Marseille, Not set
Centre Antoine Lacassagne, Nice, Not set
Hôpital Cochin, Paris, Not set
HCL - Centre Hospitalier Lyon Sud, Pierre Benite, Not set
ICO - Centre René Gauducheau, Saint-Herblain, Not set
Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, Not set
Institut Gustave Roussy, Villejuif, Not set
Hochtaunus Kliniken Bad Homburg, Bad Homburg, Not set
Universitatsklinikum Dusseldorf, Düsseldorf, Not set
University Hospital Essen, Essen, Not set
Universitätsklinikum Hamburg, Hamburg, Not set
Medical School Hannover, Hannover, Not set
University Hospital Leipzig, Leipzig, Not set
Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Not set
Universitätsklinikum Ulm, Ulm, Not set
Aretaeion Hospital, Athens, Not set
Kalamata Hospital, Kalamata, Not set
General Hospital of Patras Agios Andreas, Patras, Not set
St. Luke's Hospital, Thessaloniki, Not set
Hong Kong Sanatorium & Hospital, Happy Valley, Not set
Queen Mary Hospital, Hong Kong, Not set
Prince of Wales Hospital, New Territories, Not set
Hillel Yaffe Medical Center, Hadera, Not set
Rambam Health Care Campus, Haifa, Not set
Wolfson Medical Center, Holon, Not set
Hadassah Medical Center, Jerusalem, Not set
Sheba Medical Center, ramat GAn, Not set
Sourasky T.A.M.C., Tel Aviv-Yaffo, Not set
SOC di Oncologia Medica e Prevenzione Oncologica Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Not set
Azienda Ospedaliera Universitaria Careggi - Unita di Oncologia Ginecologica, Firenze, Not set
ASST Lecco - Ospedale Alessandro Manzoni, Lecco, Not set
Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST, Meldola, Not set
Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano, Milano, Not set
Irccs Ospedale San Raffaele-UO Ginecologia, Milan, Not set
Istituto Europeo di Oncologia, Milan, Not set
Istituto Oncologico Veneto IRCCS, Padova, Not set
Azienda Ospedaliero Universitaria Pisana, Ospedale Santa Chiara, Pisa, Not set
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Not set
Istituto Nazionale Tumori Regina Elena IRCCS, Rome, Not set
AOU Città della Salute e della Scienza di Torino - Presidio Sant'Anna, Torino, Not set
A.O. Ordine Mauriziano di Torino, Torino, Not set
Chiba Cancer Center, Chiba, Not set
The Jikei University Kashiwa Hospital, Chiba, Not set
Hyogo Cancer Center, Hyogo, Not set
St. Marianna University Hospital, Kanagawa, Not set
Mie University Hospital, Mie, Not set
Okayama University Hospital, Okayama, Not set
Saitama Medical University International Medical Center, Saitama, Not set
Shizuoka Cancer Center, Shizuoka, Not set
National Cancer Center Hospital, Tokyo, Not set
The Cancer Institute Hospital Of JFCR, Tokyo, Not set
Keimyung University Dongsan Medical Center, Dalseo-gu, Not set
National Cancer Center - Korea, Goyang-si, Not set
Seoul National University Hospital, Seoul, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Severance Hospital, Seoul, Not set
Szpitale Pomorskie Sp. z o.o., Gdynia, Not set
Uniwersyteckie Centrum Kliniczne SUM, Katowice, Not set
Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach, Siedlce, Not set
National University Hospital, Singapore, Not set
National Cancer Centre Singapore, Singapore, Not set
Complexo Hospitalario Universitario A Coruna, A Coruña, Not set
Hospital Clinic de Barcelona, Barcelona, Not set
Hospital Universitario Ciudad de Jaen, Jaén, Not set
Hospital General Universitario Gregorio Maranon, Madrid, Not set
Hospital Universitario Ramón y Cajal, Madrid, Not set
Hospital Universitario Clinico San Carlos, Madrid, Not set
Hospital Universitario Virgen de la Victoria, Málaga, Not set
Hospital Universitari Son Espases, Palma, Not set
Hospital Parc Taulí, Sabadell, Not set
Hospital Universitario Donostia, San Sebastián, Not set
Hospital Universitario La Fe - Valencia, Valencia, Not set
Kaohsiung Veterans General Hospital, Kaohsiung, Not set
Taichung Veterans General Hospital, Taichung, Not set
National Cheng Kung University Hospital, Tainan, Not set
National Taiwan University Hospital, Taipei, Not set
Mackay Memorial Hospital, Taipei, Not set
Chang Gung Memorial Hospital, Linkou, Taoyuan City, Not set
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Not set
Leeds Teaching Hospitals NHS Trust, Leeds, Not set
University Hospitals of Leicester NHS Trust-Leicester Royal Infirmary, Leicester, Not set
University College London Hospitals, London, Not set
East and North Hertfordshire NHS Trust - Mount Vernon Cancer Centre, Northwood, Not set
Conditions: Endometrial Cancer
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of California, San Diego, La Jolla, California +44 locations
University of California, San Diego, La Jolla, California
University of Southern California, Los Angeles, California
University of California, Los Angeles, Los Angeles, California
University of Colorado, Denver, Colorado
Yale University, New Haven, Connecticut
Georgetown University Medical Center, Washington, District of Columbia
Mount Sinai Medical Center, Miami Beach, Florida
Orlando Health Cancer Institute, Orlando, Florida
Moffitt Cancer Center, Tampa, Florida
University of Louisville, Louisville, Kentucky
University of Maryland, Baltimore, Maryland
Massachusetts General Hospital, Boston, Massachusetts
Karmanos Cancer Institute, Detroit, Michigan
Henry Ford Health System, Detroit, Michigan
MD Anderson at Cooper, Camden, New Jersey
Morristown Medical Center, Morristown, New Jersey
Columbia University, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
University of Cincinnati, Cincinnati, Ohio
Ohio State University, Columbus, Ohio
Avera Cancer Institute, Sioux Falls, South Dakota
Huntsman Cancer Hospital, Salt Lake City, Utah
Fred Hutchinson Cancer Research Center, Seattle, Washington
Medical College of Wisconsin, Milwaukee, Wisconsin
Princess Margaret Cancer Centre, Toronto, Ontario
Centre Léon Berard, Lyon, Not set
Klinikum rechts der Isar der Technischen Universität München, München, Bavaria
Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen
Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein
Laiko General Hospital of Athens, Athens, Attiki
Attikon University General Hospital, Athens, Attiki
Hospital Universitario Marques de Valdecilla, Santander, Cantabria
University Hospital Vall d'Hebron, Barcelona, Not set
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Not set
Hospital General Universitario Gregorio Marañón, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Universitario HM Sanchinarro, Madrid, Not set
Hospital Regional Universitario de Malaga - Hospital General, Málaga, Not set
Universitätsspital Basel, Basel, Not set
Universitaetsspital Bern, Bern, Not set
Centre Hospitalier Universitaire Vaudois, Lausanne, Not set
Guy's Hospital, London, England
The Royal Marsden NHS Foundation Trust, London, England
Bristol Haematology and Oncology Centre, Bristol, Not set
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Active Not Recruiting
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UCSF Helen Diller Family CCC, San Francisco, California +38 locations
UCSF Helen Diller Family CCC, San Francisco, California
Washington University School of Medicine, Saint Louis, Missouri
Levine Cancer Institute, Charlotte, North Carolina
Ohio State University, Columbus, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Texas Oncology - Gulf Coast, The Woodlands, Texas
Virginia Oncology Associates, Norfolk, Virginia
University of Washington - Seattle Cancer Care Alliance, Seattle, Washington
Cabrini Hospital, Malvern, Victoria
Princess Margaret Cancer Center, Toronto, Ontario
McGill University Health Centre - Glen Site, Montreal, Quebec
Gynekologicko-porodnicka klinika, Prague, Not set
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, Not set
Centre Francois Baclesse, Caen, Not set
Centre Leon Berard, Lyon, Not set
Groupe Hospitalier Diaconesses, Paris, Not set
Centre Eugène Marquis, Rennes, Not set
Institut Claudius Regaud, Toulouse, Not set
Gustave Roussy, Villejuif CEDEX, Not set
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Not set
Universitätsklinikum Mannheim, Mannheim, Not set
Istituto Tumori Napoli, Napoli, Campania
Policlinico Universitario Agostino Gemelli, Roma, Lazio
IRCCS S. Raffaele, Milano, Lombardia
A.O. U. Consorziale Policlinico di Bari, Bari, Puglia
Samsung Medical Center, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Asan Medical Center, Seoul, Not set
Institutio Catalan De Oncologia, Barcelona, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Clinico Universitario Virgen de la Victoria, Malaga, Not set
Hôpitaux Universitaires de Genève, Genève, Not set
Adana Baskent University Medical Faculty; Oncology, Adana, Not set
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü, Ankara, Not set
Koc University Medical Faculty; Department of Gynecology & Obstetrics, Istanbul, Not set
Western General Hospital, Edinburgh, Not set
University College London Hospitals NHS Foundation Trust - University College Hospital, London, Not set
Conditions: Ovarian Cancer
49 - 60 of 293